the challenge of recurrent hepatitis c virus in liver transplant recipients
Clicks: 74
ID: 184781
2004
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
21.9
/100
74 views
14 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #206 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Hepatitis C virus (HCV) has become the leading indication for liver
transplantation (LT) worldwide. Short-term graft and patient survival
after LT in these individuals is comparable with other indications for
LT. There is, however, a disturbing trend for decreased survival over the
longer term. The natural history of HCV infection after LT is evolving.
Its early recurrence and the wide spectrum of recurrent disease is recognized,
from minimal histological and clinical disease to very aggressive
forms of hepatic damage such as fibrosing cholestatic hepatitis. There is
growing concern that recurrent HCV is becoming more aggressive.
Although many factors have been implicated, the causes have not
been fully elucidated. Interferon-based antiviral therapy is challenging
to use in this patient population because of significant toxicity.
Nevertheless, these agents have some efficacy, and pegylated interferons,
which are now being used more frequently, achieve superior
response rates. The role of liver retransplantation in this patient population
is controversial, because of both a reduced survival rate and an
overall shortage of organ donors. The present review discusses the
challenges that occur in LT recipients with HCV.
| Reference Key |
marotta2004canadianthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Paul J Marotta |
| Journal | indian journal of pharmacology |
| Year | 2004 |
| DOI |
10.1155/2004/759124
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.